| Interpreting the benefit and risk data in between-drug comparisons: Illustration of the challenges using the example of mefenamic acid versus ibuprofen A Farkouh, M Hemetsberger, CR Noe, C Baumgärtel Pharmaceutics 14 (10), 2240, 2022 | 10 | 2022 |
| Sex-related differences in drugs with anti-inflammatory properties A Farkouh, C Baumgärtel, R Gottardi, M Hemetsberger, M Czejka, ... Journal of clinical medicine 10 (7), 1441, 2021 | 40 | 2021 |
| Why are self-medication opportunities limited in Austria? An interview study and comparison with other countries NJ Gauld, CA Baumgärtel, SA Buetow Plos one 16 (1), e0245504, 2021 | | 2021 |
| Mini-review: medication safety of red yeast rice products A Farkouh, C Baumgärtel International Journal of General Medicine, 167-171, 2019 | 38 | 2019 |
| Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context B Godman, A Kurdi, A Leporowski, A Morton, C Baumgärtel, T Bochenek, ... Medical Research Archives 5 (3), 2017 | 21 | 2017 |
| Austrian medicines authority positive towards biosimilar interchangeability C Baumgärtel Generics and Biosimilars Initiative Journal (GaBI Journal) 6 (1), 41, 2017 | 1 | 2017 |
| Prevalence and determinants of unintended double medication of antihypertensive, lipid‐lowering, and hypoglycemic drugs in Austria: a nationwide cohort study G Heinze, LM Jandeck, M Hronsky, B Reichardt, C Baumgärtel, A Bucsics, ... Pharmacoepidemiology and Drug Safety 25 (1), 90-99, 2016 | 17 | 2016 |
| Bioequivalence of narrow therapeutic index drugs and immunosuppressives C Baumgärtel, B Godman Generics and Biosimilars Initiative Journal 4 (4), 2015 | 9 | 2015 |
| Are generic immunosuppressants safe and effective? B Godman, C Baumgärtel Bmj 350, 2015 | 18 | 2015 |
| Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study G Heinze, M Hronsky, B Reichardt, C Baumgärtel, M Müllner, A Bucsics, ... Applied health economics and health policy 13, 193-205, 2015 | 26 | 2015 |
| Generics authorization--groundbreaking regulatory approach to closer international cooperation on the rise--IGDRP C Baumgartel, K Gazda-Pleban Generics and Biosimilars Initiative Journal 4 (1), 48-49, 2015 | | 2015 |
| Generic pregabalin: current situation and implications for health authorities, generics and biosimilars manufacturers in the future B Godman, M Wilcock, A Martin, S Bryson, C Baumgärtel, T Bochenek, ... Generics and Biosimilars Initiative Journal 4 (3), 125-135, 2015 | 25 | 2015 |
| Substantial savings with generics in Austria–and still room for more C Baumgärtel GaBI Journal 4 (3), 2, 2015 | 4 | 2015 |
| Dabigatran-a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs B Godman, RE Malmström, E Diogene, S Jayathissa, S McTaggart, T Cars, ... Frontiers in pharmacology 5, 109, 2014 | 62 | 2014 |
| New EU guidance for the evaluation of medicinal products with modified drug release will be finished by the middle of 2014 C Baumgartel Generics and Biosimilars Initiative Journal 3 (2), 99-100, 2014 | | 2014 |
| New product-specific bioequivalence guidance C Baumgartel Generics and Biosimilars Initiative Journal 3 (1), 29-30, 2014 | 1 | 2014 |
| Personalizing health care: feasibility and future implications B Godman, AE Finlayson, PK Cheema, E Zebedin-Brandl, ... BMC medicine 11, 1-23, 2013 | 126 | 2013 |
| Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs RE Malmström, BB Godman, E Diogene, C Baumgärtel, M Bennie, ... Frontiers in pharmacology 4, 39, 2013 | 121 | 2013 |
| Austria increases dialogue in order to involve physicians more with biosimilars C Baumgartel GaBI Journal 2, 8, 2013 | 4 | 2013 |
| Generika in Österreich: und ihre Bedeutung für das Gesundheitssytem C Baumgärtel AV Akademikerverlag, 2013 | 2 | 2013 |
